Table 2.

Most common (≥10%) treatment-related adverse events (maximum grade, all cycles)

Veliparib dose level
Total number of patients with event10 mg N = 720 mg N = 940 mg N = 1250 mg N = 7
Adverse eventN = 35 (%)All (%)Gr ≥ 3 (%)All (%)Gr ≥ 3 (%)All (%)Gr ≥ 3 (%)All (%)Gr ≥ 3 (%)
Diarrhea22 (63)5 (71)1 (14)5 (56)1 (11)8 (67)4 (57)1 (14)
Fatigue21 (60)5 (71)1 (14)5 (56)2 (22)6 (50)5 (71)
Nausea21 (60)4 (57)7 (78)6 (50)4 (57)
Leukopenia17 (49)4 (57)3 (43)4 (44)1 (11)4 (33)2 (17)5 (71)2 (29)
Neutropenia17 (49)4 (57)2 (29)4 (44)2 (22)5 (42)2 (17)4 (57)3 (43)
Anemia13 (37)4 (57)1 (14)1 (11)5 (42)3 (43)
Anorexia11 (31)3 (43)1 (11)4 (33)3 (43)
Vomiting9 (26)2 (29)3 (33)3 (25)1 (14)
Alopecia7 (20)1 (14)1 (11)4 (33)1 (14)
Lymphopenia6 (17)2 (29)2 (29)1 (11)1 (11)3 (25)
Dehydration5 (14)1 (14)1 (14)2 (22)1 (8)1 (14)
Hypoalbuminemia5 (14)1 (14)1 (11)3 (25)
Abdominal pain4 (11)1 (14)1 (11)1 (8)1 (14)